In section Market Quotes

Keros Therapeutics Authorizes Up to $5 Million Share Buyback

Keros Therapeutics’ board approved a share buyback of up to $5 million after the company received a $20 million development milestone payment from Takeda Pharmaceuticals under a licensing agreement.

Keros Therapeutics Authorizes Up to $5 Million Share Buyback

The payment is tied to elritercept, which Keros is developing as a blood platelet producer. The drug reached a clinical-trial milestone with the first patient completing dosing.

Keros said the buyback authorization may be modified or discontinued at any time.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!